AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14998423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol LP 200 mg
Number of subjects: 30
Study 14998423 — intervention group
Group type: COMPARATOR
Intervention: Topalgic 4 x 50mg
Number of subjects: 30
Study 14998423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol LP 200 mg (fasting state)
Number of subjects: 30
Study 14998423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol LP 200 mg (fed state)
Number of subjects: 30
Study 10913727 — intervention group
Group type: EXPERIMENTAL
Intervention: carnitine supplementation
Number of subjects: 20
Study 10913727 — intervention group
Group type: COMPARATOR
Intervention: placebo supplementation
Number of subjects: 20
Study 9368873 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence screen detected
Number of subjects: 250
Study 9368873 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously screened
Number of subjects: 250
Study 9368873 — intervention group
Group type: COMPARATOR
Intervention: Never screened
Number of subjects: 250
Study 2062489 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser treatment
Number of subjects: 44
Study 2062489 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 44
Study 6849741 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin 50 mg
Number of subjects: 5
Study 6849741 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin 100 mg
Number of subjects: 5
Study 6849741 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin 25 mg
Number of subjects: 5
Study 6849741 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (all doses)
Number of subjects: 5
Study 30736052 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial-stabilized (MS)
Number of subjects: 50
Study 30736052 — intervention group
Group type: COMPARATOR
Intervention: Posterior-stabilized (PS)
Number of subjects: 50
Study 30552587 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPT 0.17 mg/kg/day (n = 37)
Number of subjects: 75
Study 30552587 — intervention group
Group type: COMPARATOR
Intervention: PR-Tac 0.20 mg/kg/day (n = 38)
Number of subjects: 75
Study 28050798 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU every 2 weeks for 6 months)
Number of subjects: 58
Study 28050798 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 58
Study 26941199 — intervention group
Group type: EXPERIMENTAL
Intervention: PICN 260 mg/m2
Number of subjects: 180
Study 26941199 — intervention group
Group type: EXPERIMENTAL
Intervention: PICN 295 mg/m2
Number of subjects: 180
Study 26941199 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel 260 mg/m2
Number of subjects: 180
Study 25326051 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0
Study 25326051 — intervention group
Group type: COMPARATOR
Intervention: Baseline serotonin levels
Number of subjects: 0
Study 22495466 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization plus standard medical therapy
Number of subjects: 84
Study 22495466 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 84
Study 20028443 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative 1550-nm erbium-doped fractional photothermolysis systems (FPS)
Number of subjects: 8
Study 20028443 — intervention group
Group type: COMPARATOR
Intervention: Ablative 10 600-nm carbon dioxide fractional laser systems (CO(2) FS)
Number of subjects: 8
Study 18404122 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-6 fatty acids treatment before and after PRK
Number of subjects: 80
Study 15842976 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 0
Study 12432175 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal carbohydrases (Carbogen) with meal replacement bar (MBR)
Number of subjects: 5
Study 12432175 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CaCO3) with meal replacement bar (MBR)
Number of subjects: 5
Study 10500327 — intervention group
Group type: EXPERIMENTAL
Intervention: Waffles containing Enterococcus faecium M-74
Number of subjects: 0
Study 8942009 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 50 micrograms twice daily
Number of subjects: 24
Study 8942009 — intervention group
Group type: COMPARATOR
Intervention: salbutamol and theophylline (control)
Number of subjects: 24
Study 2025069 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary repair or resection and anastomosis
Number of subjects: 56
Study 2025069 — intervention group
Group type: COMPARATOR
Intervention: Diversion (24 colostomy, 3 ileostomy, 1 jejunostomy)
Number of subjects: 56
Study 906784 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallamine 0.3 mg/kg
Number of subjects: 60
Study 906784 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallamine 0.4 mg/kg
Number of subjects: 60
Study 906784 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallamine 0.5 mg/kg
Number of subjects: 60
Study 31768936 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole (4-MP) administered intravenously alongside APAP.
Number of subjects: 5
Study 31768936 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (APAP) alone without 4-MP.
Number of subjects: 5
Study 31738798 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including participatory ergonomics, health promotion activities, and case management for one year.
Number of subjects: 473
Study 31738798 — intervention group
Group type: COMPARATOR
Intervention: Usual occupational health care (Control group).
Number of subjects: 473
Study 27872357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) pediatric suspension 7.5 mg/kg
Number of subjects: 0
Study 27872357 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (APAP) suspension 10 to 15 mg/kg
Number of subjects: 0
Study 26124203 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab (11 mg/kg every 3 weeks)
Number of subjects: 79
Study 26124203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 23271090 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicopter emergency medical systems (HEMS)
Number of subjects: 192422
Study 23271090 — intervention group
Group type: COMPARATOR
Intervention: Ground ambulance
Number of subjects: 192422
Study 21630245 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly
Number of subjects: 566
Study 21630245 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine titrated to a maximum of 3 gm/day
Number of subjects: 566
Study 19307812 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb technique (TT)
Number of subjects: 64
Study 19307812 — intervention group
Group type: COMPARATOR
Intervention: Two-finger technique (TF)
Number of subjects: 64
Study 19307812 — intervention group
Group type: COMPARATOR
Intervention: One-hand technique (OH)
Number of subjects: 64
Study 19307812 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-hand technique (TH)
Number of subjects: 64
Study 22294408 — intervention group
Group type: EXPERIMENTAL
Intervention: Delis‐Kaplan Executive Function System (D‐KEFS) Sorting Test
Number of subjects: 167
Study 22294408 — intervention group
Group type: EXPERIMENTAL
Intervention: WMS‐III Immediate Memory Primary Index (IMI)
Number of subjects: 167
Study 22294408 — intervention group
Group type: EXPERIMENTAL
Intervention: WMS‐III Working Memory Primary Index (WMI)
Number of subjects: 167
Study 15880316 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive enteral or parenteral nutrition (1000 kcal/d until patients did not wish to continue)
Number of subjects: 80
Study 15880316 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive enteral or parenteral nutrition
Number of subjects: 80
Study 15880316 — intervention group
Group type: COMPARATOR
Intervention: Oral nutrition only (control)
Number of subjects: 80
Study 15880316 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral feeding
Number of subjects: 80
Study 15880316 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 80
Study 12865481 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) injections
Number of subjects: 28
Study 12865481 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training and placebo (RT+P)
Number of subjects: 28
Study 12865481 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly injections of testosterone (T; 100 mg/week)
Number of subjects: 28
Study 12865481 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training and testosterone (RT+T)
Number of subjects: 28
Study 12865481 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including MA)
Number of subjects: 28
Study 10215942 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FVIII (rFVIII-KOGENATE)
Number of subjects: 58
Study 7612052 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral racemic propafenone preparation (300 mg)
Number of subjects: 24
Study 2696433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (L) added to formula
Number of subjects: 0
Study 2696433 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and lactoferrin (LF) added to formula
Number of subjects: 0
Study 2696433 — intervention group
Group type: COMPARATOR
Intervention: No added iron and no added lactoferrin (basic)
Number of subjects: 0
Study 16632 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol
Number of subjects: 6
Study 16632 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 16632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 12151246 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural manual therapy technique
Number of subjects: 30
Study 12151246 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect manual therapy techniques
Number of subjects: 30
Study 12151246 — intervention group
Group type: COMPARATOR
Intervention: Control group (crossed over to neural manual therapy after 8 weeks)
Number of subjects: 30
Study 30174418 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT) of 1,064 nm, 60 J/cm2, 10 minutes
Number of subjects: 68
Study 30174418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) of 785 nm, 8 J/cm2, 8 minutes
Number of subjects: 68
Study 30174418 — intervention group
Group type: COMPARATOR
Intervention: Sham (HILT placebo)
Number of subjects: 68
Study 30174418 — intervention group
Group type: COMPARATOR
Intervention: Sham (LLLT placebo)
Number of subjects: 68
Study 27080931 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Number of subjects: 126
Study 27080931 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 126
Study 24751502 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 μg/kg/min continuous infusion for 24 h)
Number of subjects: 30
Study 24751502 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30
Study 24751502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22810741 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis with mexidol
Number of subjects: 116
Study 22810741 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis with standard therapy
Number of subjects: 116
Study 20233178 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (42 mg/day)
Number of subjects: 12
Study 20233178 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 12
Study 18384391 — intervention group
Group type: EXPERIMENTAL
Intervention: Local minocycline microspheres
Number of subjects: 60
Study 18384391 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 60
Study 18384391 — intervention group
Group type: EXPERIMENTAL
Intervention: Local minocycline microspheres (in smokers)
Number of subjects: 60
Study 18384391 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (in smokers)
Number of subjects: 60
Study 15607868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg)
Number of subjects: 44
Study 15607868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15607868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 44
Study 12107600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (500 microg twice daily)
Number of subjects: 12
Study 12107600 — intervention group
Group type: COMPARATOR
Intervention: Sotalol (160 mg twice daily)
Number of subjects: 12
Study 10431120 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T booster immunization
Number of subjects: 348
Study 10431120 — intervention group
Group type: COMPARATOR
Intervention: PRP-D priming
Number of subjects: 348
Study 10431120 — intervention group
Group type: COMPARATOR
Intervention: PRP-T priming
Number of subjects: 348
Study 10431120 — intervention group
Group type: COMPARATOR
Intervention: No additional PRP-T
Number of subjects: 348
Study 7599249 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment and intervention team (GAIT) services
Number of subjects: 108
Study 7599249 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital care (Control)
Number of subjects: 108
Study 2296626 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 24
Study 2296626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 352088 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% guanethidine/1% adrenaline combination
Number of subjects: 63
Study 352088 — intervention group
Group type: COMPARATOR
Intervention: 5% guanethidine alone
Number of subjects: 63
Study 352088 — intervention group
Group type: COMPARATOR
Intervention: 1% adrenaline alone
Number of subjects: 63
Study 31553474 — intervention group
Group type: COMPARATOR
Intervention: Randomized control trial (uninformative visits)
Number of subjects: 0
Study 31553474 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR data (potentially informative visits)
Number of subjects: 0
Study 31553474 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR data with some uninformative visits
Number of subjects: 0
Study 28153768 — intervention group
Group type: EXPERIMENTAL
Intervention: PABC intervention (Months 1-3)
Number of subjects: 32
Study 28153768 — intervention group
Group type: COMPARATOR
Intervention: No physical activity intervention (attention control, Months 1-3)
Number of subjects: 32
Study 28153768 — intervention group
Group type: COMPARATOR
Intervention: No contact (intervention wash-out, Months 4-6)
Number of subjects: 32
Study 25986699 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing Parenting Skills (EPaS) 2014 programme
Number of subjects: 60
Study 25986699 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list treatment as usual control group
Number of subjects: 60
Study 24183218 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil 5%
Number of subjects: 110
Study 24183218 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical adenosine 0.75%
Number of subjects: 110
Study 21810107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy with transference interpretation
Number of subjects: 100
Study 21810107 — intervention group
Group type: COMPARATOR
Intervention: Dynamic psychotherapy without transference interpretation
Number of subjects: 100
Study 20024680 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/valsartan 320 mg/hydrochlorothiazide 25 mg (triple therapy)
Number of subjects: 0
Study 20024680 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 320 mg/hydrochlorothiazide 25 mg (dual therapy)
Number of subjects: 0
Study 20024680 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg/valsartan 320 mg (dual therapy)
Number of subjects: 0
Study 20024680 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg/hydrochlorothiazide 25 mg (dual therapy)
Number of subjects: 0
Study 17219991 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivin expression in differentiated thyroid carcinomas
Number of subjects: 67
Study 17219991 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF expression in differentiated thyroid carcinomas
Number of subjects: 67
Study 17219991 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Survivin with VEGF and MVD
Number of subjects: 67
Study 17219991 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical stages, tumor complete capsule, and lymph node metastasis
Number of subjects: 67
Study 17219991 — intervention group
Group type: COMPARATOR
Intervention: Survivin expression in thyroid adenoma and normal thyroid tissues
Number of subjects: 67
Study 12963991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur suppositories (750 mg/day) from 1 to 2 weeks prior to surgery, to 2 weeks following surgery, followed by oral administration of tegafur and uracil (UFT) (260 mg/m(2)) for 1 year
Number of subjects: 0
Study 12963991 — intervention group
Group type: COMPARATOR
Intervention: UFT (260 mg/m(2)) for 1 year beginning week 2 after surgery
Number of subjects: 0
Study 10934462 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported history of cataract at baseline
Number of subjects: 18669
Study 10934462 — intervention group
Group type: COMPARATOR
Intervention: Men without reported cataract
Number of subjects: 18669
Study 8750446 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent form provided at least 24 hours prior to procedure
Number of subjects: 160
Study 8750446 — intervention group
Group type: COMPARATOR
Intervention: Consent form provided at the time of the procedure
Number of subjects: 160
Study 1574257 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen receptor assay performed at the largest cross-section of a large tumor
Number of subjects: 35
Study 1574257 — intervention group
Group type: COMPARATOR
Intervention: Estrogen receptor assay performed on a small random part of a large tumor
Number of subjects: 35
Study 1574257 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple assays of ER levels in tumors
Number of subjects: 35
Study 4081525 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon nasal spray (IFN-alpha), 50,000 IU per day, sprayed twice a day.
Number of subjects: 73
Study 4081525 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control).
Number of subjects: 73
Study 30549143 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Time (TST)
Number of subjects: 41
Study 30549143 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 41
Study 30549143 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 41
Study 29234869 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 14
Study 29234869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 14
Study 29234869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 27541801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous MTX (4 mg/kg) monthly for 5 months with folinic acid rescue 24 hours after MTX administration
Number of subjects: 12
Study 24326003 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg/day
Number of subjects: 208
Study 24326003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 22019270 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 562
Study 22019270 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 562
Study 21313927 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biomarkers (Cardiac Troponin T, N-Terminal pro-Brain Natriuretic Peptide, high sensitivity C-Reactive Protein, blood glucose)
Number of subjects: 1731
Study 21313927 — intervention group
Group type: COMPARATOR
Intervention: NNE preoperative risk prediction model without biomarkers
Number of subjects: 1731
Study 17661239 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Flex mode (level 2) for 6 weeks
Number of subjects: 20
Study 17661239 — intervention group
Group type: COMPARATOR
Intervention: fix CPAP for 6 weeks
Number of subjects: 20
Study 17661239 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Flex mode
Number of subjects: 20
Study 17661239 — intervention group
Group type: COMPARATOR
Intervention: fix CPAP
Number of subjects: 20
Study 16261288 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic regimen with half reteplase (r-PA) dose plus abciximab
Number of subjects: 38
Study 16261288 — intervention group
Group type: COMPARATOR
Intervention: Full dose r-PA
Number of subjects: 38
Study 12239969 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth I (BI)
Number of subjects: 45
Study 12239969 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth II (BII)
Number of subjects: 45
Study 12239969 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y (Roux)
Number of subjects: 45
Study 10391812 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives of persons with type 2 diabetes
Number of subjects: 26
Study 10391812 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 8699540 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment interventions (4-month duration)
Number of subjects: 184
Study 1852400 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable (RGP) lenses worn overnight
Number of subjects: 12
Study 1852400 — intervention group
Group type: COMPARATOR
Intervention: Control (no lens) condition
Number of subjects: 12
Study 1852400 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 h closed-eye condition
Number of subjects: 12
Study 1852400 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft lens types worn overnight
Number of subjects: 12
Study 6299329 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre diet
Number of subjects: 0
Study 6299329 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 0
Study 29794108 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway clearance physiotherapy (ACT) prior to cardiopulmonary exercise testing (CPET)
Number of subjects: 12
Study 28199679 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA/rAd5 vaccine
Number of subjects: 2504
Study 28199679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2504
Study 25733243 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg PO
Number of subjects: 88